Evidence map›Paper›PMID 27440044›Full record

ArticleThe Journal of biological chemistry2016

An Organic Anion Transporter 1 (OAT1)-centered Metabolic Network.

Henry C Liu, Neema Jamshidi, Yuchen Chen, Satish A Eraly, Sai Yee Cho, Vibha Bhatnagar, Wei Wu, Kevin T Bush, Ruben Abagyan, Bernhard O Palsson and 1 more

Open access · hybridAbstract read
In one paragraph

Article in The Journal of biological chemistry, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
2.4field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 45 citations in OpenAlex.

  1. Pharmaceutics · 2026
    Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 2 countries.

Henry C LiuFrom the Departments of Bioengineering.
Neema JamshidiFrom the Departments of Bioengineering.
Yuchen ChenBioinformatics and Systems Biology Graduate Program.
Satish A EralyMedicine.
Sai Yee ChoChemistry and Biochemistry.
Vibha BhatnagarFamily and Preventative Medicine.
Wei WuMedicine.
Kevin T BushPediatrics, and.
Ruben AbagyanSkaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, La Jolla, California 92093.
Bernhard O PalssonFrom the Departments of Bioengineering.
Sanjay K NigamMedicine, Pediatrics, and Cellular and Molecular Medicine, snigam@ucsd.edu.
Bioengineering Center · RUPediatrics and Genetics · USDay Family Medicine · USUniversity of Montana · US

Funding

Macromolecular DockingR01GM071872 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI ABAGYAN, RUBEN · 2004 to 2017
$4.2M
Substrate Specificity of the Choroid Plexus and Kidney Transporter Oat1R01GM098449 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI NIGAM, SANJAY K · 2012 to 2015
$2.1M
Structure Function Analysis of the Multi-specific Drug Transporter OCT1R01GM104098 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI NIGAM, SANJAY K · 2013 to 2016
$1.6M
NIGMS NIH HHS R01 GM071872NIGMS NIH HHS R01 GM098449NIGMS NIH HHS R01 GM104098
6 · The paper itself

Abstract

There has been a recent interest in the broader physiological importance of multispecific "drug" transporters of the SLC and ABC transporter families. Here, a novel multi-tiered systems biology approach was used to predict metabolites and signaling molecules potentially affected by the in vivo deletion of organic anion transporter 1 (Oat1, Slc22a6, originally NKT), a major kidney-expressed drug transporter. Validation of some predictions in wet-lab assays, together with re-evaluation of existing transport and knock-out metabolomics data, generated an experimentally validated, confidence ranked set of OAT1-interacting endogenous compounds enabling construction of an "OAT1-centered metabolic interaction network." Pathway and enrichment analysis indicated an important role for OAT1 in metabolism involving: the TCA cycle, tryptophan and other amino acids, fatty acids, prostaglandins, cyclic nucleotides, odorants, polyamines, and vitamins. The partly validated reconstructed network is also consistent with a major role for OAT1 in modulating metabolic and signaling pathways involving uric acid, gut microbiome products, and so-called uremic toxins accumulating in chronic kidney disease. Together, the findings are compatible with the hypothesized role of drug transporters in remote inter-organ and inter-organismal communication: The Remote Sensing and Signaling Hypothesis (Nigam, S. K. (2015) Nat. Rev. Drug Disc. 14, 29). The fact that OAT1 can affect many systemic biological pathways suggests that drug-metabolite interactions need to be considered beyond simple competition for the drug transporter itself and may explain aspects of drug-induced metabolic syndrome. Our approach should provide novel mechanistic insights into the role of OAT1 and other drug transporters implicated in metabolic diseases like gout, diabetes, and chronic kidney disease.

Indexed as

Models, BiologicalAnimalsMetabolomeMiceOrganic Anion Transport Protein 1Organic Anion Transport Protein 1Slc22a6 protein, mouseABC transporterchronic kidney diseasediabetesgenome-scale metabolic reconstructionkidneymicrobiomepharmacophoreReconSLC transportersystems biology

Identifiers

PMID27440044
PMCPMC5016685
OpenAlexW2515638948

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.